文献速递血栓与止血

澳大利亚大型队列中疫苗诱导的血栓性血小板减少症(VITT)抗血小板因子4抗体免疫学检测评估:一项纳入1284例患者的多中心研究

Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients.
PubMed 文献 · J Thromb Haemost · 2022-09-29

该多中心研究在1284例患者中评估抗血小板因子4(PF4)抗体检测对疫苗诱导的血栓性血小板减少症(VITT)的诊断价值。首次就诊时190/1284(14.8%)ELISA检测阳性,而化学发光法抗PF4检测多数(445/460;96.7%)为阴性。功能试验显示ELISA光密度中位数较高与功能阳性相关,且14.8%-36.0%的ELISA阴性样本存在功能阳性,提示HPIA IgG ELISA可能漏诊部分VITT病例。

要点

  • 首次就诊时HPIA IgG ELISA抗PF4抗体阳性率为14.8%(190/1284)。
  • 化学发光法抗PF4检测阴性率为96.7%(445/460)。
  • ELISA阴性样本中14.8%-36.0%功能试验阳性,提示单用ELISA可能漏诊。

核心结论

  • 这是迄今最大的多中心VITT抗PF4检测评估研究。
  • 部分患者检测结果不一致(ELISA与ELISA或ELISA与功能试验),凸显依赖单一方法检测PF4抗体的局限性。
  • 结果也提示VITT表型检测表现和病理机制存在变异性。

研究设计与样本

  • 多中心研究,纳入1284例患者,为期12个月。
  • 采用Asserachrom HPIA IgG ELISA检测抗PF4抗体。
  • 部分队列补充三种其他ELISA方法(n=78-179)、三种功能试验(流式细胞术、5-羟色胺释放试验和/或Multiplate;n=476)及快速免疫化学发光抗PF4检测(n=460)。

主要发现

  • 首次就诊时,190/1284(14.8%)ELISA检测阳性。
  • 化学发光法抗PF4检测结果多数为阴性(445/460;96.7%)。
  • 所有功能试验均显示较高的ELISA光密度中位数与功能阳性相关,且ELISA阳性率高(64.0%至85.2%)。
  • 14.8%-36.0%的ELISA阴性样本存在功能阳性,提示HPIA IgG ELISA可能使多达三分之一可评估病例出现VITT假阴性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare complication of adenovirus-based vaccines aimed to prevent and minimize COVID-19 and related pathophysiology. OBJECTIVES: To describe patterns of testing for anti-platelet factor 4 (PF4) antibodies using various ELISA assays in a large Australian cohort and comparative functional platelet activation assays in a subset. PATIENTS/METHODS: Asserachrom HPIA IgG ELISA was performed in 1284 patients over a period of 12 months, supplemented in select cohorts by comparative ELISA using three other methods (n = 78-179), three different functional assays (flow cytometry, serotonin release assay, and/or Multiplate; n = 476), and rapid immunological chemiluminescence anti-PF4 assay (n = 460), in a multicenter study. RESULTS: For first episode presentations, 190/1284 (14.8%) ELISA tests were positive. Conversely, most (445/460; 96.7%) chemiluminescence anti-PF4 test results were negative. All functional assays showed associations of higher median ELISA optical density with functional positivity and with high rates of ELISA positivity (64.0% to 85.2%). Data also identified functional positivity in 14.8%-36.0% of ELISA negative samples, suggesting false negative VITT by HPIA IgG ELISA in upward of one third of assessable cases. CONCLUSION: To our knowledge, this is the largest multicenter evaluation of anti-PF4 testing for investigation of VITT. Discrepancies in test results (ELISA vs. ELISA or ELISA vs. functional assay) in some patients highlighted limitations in relying on single methods (ELISA and functional) for PF4 antibody detection in VITT, and also highlights the variability in phenotypic test presentation and pathomechanism of VITT.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Favaloro EJ, Clifford J, Leitinger E, et al. Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients. J Thromb Haemost. 2022. PMID: 36107495. doi:10.1111/jth.15881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。